Syncona
Limited
Autolus files for
proposed initial public offering in the
United States
8 May 2018
Syncona Ltd, a leading healthcare company focused on investing
in and building global leaders in life science, today notes that
its portfolio company Autolus Therapeutics Limited (to be
reorganised as Autolus Therapeutics plc) (“Autolus”) has filed a
registration statement on Form F-1 (“Registration Statement”) with
the U.S. Securities and Exchange Commission (the “SEC”) relating to
a proposed initial public offering (“IPO”) in the United States of its American Depositary
Shares (“ADSs”), each representing one ordinary share. All ADSs to
be sold in the proposed IPO will be offered by Autolus. Autolus
intends to apply to list its ADSs on the Nasdaq Global Market under
the ticker symbol “AUTL”. The number of ADSs to be sold and the
pricing terms for the proposed IPO have not yet been
determined.
The Registration Statement relating to the ADSs has been filed
with the SEC but has not yet become effective. The ADSs may not be
sold nor may offers to buy be accepted prior to the time the
Registration Statement becomes effective.
The Registration Statement can be accessed through the SEC’s
EDGAR Database. Syncona notes that the Registration Statement
contains further information relating to Autolus, and further notes
that the information includes previously unpublished information
relating to Autolus’ current clinical trials.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. When available, copies of
the preliminary prospectus can be obtained from either of the joint
book-running managers for the offering, Goldman Sachs & Co.
LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at +1 866
471 2526 or by email at prospectusgroup-ny@ny.email.gs.com; or
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, or by telephone at + 1 877 547 6340, or by email
at Prospectus_Department@Jefferies.com.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Forward-looking statements – this
announcement contains certain forward-looking statements with
respect to the portfolio of investments of Syncona Ltd. These
statements and forecasts involve risk and uncertainty because they
relate to events and depend upon circumstances that may or may not
occur in the future. There are a number of factors that could cause
actual results or developments to differ materially from those
expressed or implied by these forward-looking statements and
forecasts. Nothing in this announcement should be construed as a
profit forecast.
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders. Our current investment portfolio consists
of seven high quality companies in life science and a leading range
of fund investments.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We are
established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.
Our fund investments represent a productively deployed evergreen
funding base which enables us to take a long term approach to
investing in life sciences as we target the best new opportunities
and support our existing portfolio companies to grow and
succeed.
Syncona is aligned with two of the premium charitable funders in
UK science, the Wellcome Trust, original founder of Syncona, and
Cancer Research UK, both of which are significant shareholders in
our business. We make a donation of 0.3% of Net Asset Value
to a range of charities each year.
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.